Skip to content

A cross-Sectional Study on the Metabolomics of Sex Hormone Profiles in Patients with Benign Prostatic Hyperplasia

A cross-Sectional Study on the Metabolomics of Sex Hormone Profiles in Patients with Benign Prostatic Hyperplasia

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500112271
Enrollment
Unknown
Registered
2025-11-12
Start date
2025-12-01
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Benign prostatic hyperplasia

Interventions

Non-BPH Group:None

Sponsors

Peking University Shenzhen Hospital
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
50 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Diagnosed with benign prostatic hyperplasia; 2. Age should be between 50 and 80 years old; 3. Project participants have the ability to make independent decisions, agree to participate in this study, and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1.Patients diagnosed with prostate cancer; 2.Patients who have used medications within the past 6 months that may affect prostate volume, International Prostate Symptom Score (IPSS), Quality of Life (QoL) score (0-6), International Consultation on Incontinence Questionnaire-Male Lower Urinary Tract Symptoms (ICIQ-MLUTS), or voiding diary results (including but not limited to 5a-reductase inhibitors, a-blockers, M-receptor antagonists, herbal preparations, traditional Chinese medicines, or Chinese patent drugs); 3.Patients who have used medications within the past 6 months that may influence sex hormone metabolome levels (including but not limited to testosterone undecanoate formulations or gels, dihydrotestosterone formulations or gels, endocrine therapy drugs for prostate cancer, estrogen formulations or gels, or traditional Chinese medicines or Chinese patent drugs for kidney tonification and yang enhancement); 4.Patients with congenital abnormalities of the reproductive system; 5.Patients with genital infections, acute urinary tract infections, or prostatitis; 6.Patients with steroid hormone-related endocrine disorders; 7.Patients currently taking psychotropic or neurological medications; 8.Patients with positive HIV or syphilis test results; 9.Patients with abnormal liver or kidney function (total bilirubin >17.1 µmol/L; creatinine >176.8 µmol/L); 10.Patients deemed by the investigator unsuitable for participation in the study;

Design outcomes

Primary

MeasureTime frame
prostate volume;QoL score;IPSS score;ICIQ-MLUTS;

Countries

China

Contacts

Public ContactYang Yu

Peking University Shenzhen Hospital

13924676140@163.com+86 755 83923333

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026